Canada markets closed

AstraZeneca PLC (AZN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
65.53-0.46 (-0.70%)
At close: 04:00PM EST
65.60 +0.07 (+0.11%)
After hours: 07:48PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close65.99
Open65.40
Bid65.56 x 1800
Ask65.52 x 1100
Day's Range65.19 - 65.78
52 Week Range52.65 - 72.12
Volume3,176,369
Avg. Volume5,055,911
Market Cap203.117B
Beta (5Y Monthly)0.23
PE Ratio (TTM)102.39
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.45 (2.18%)
Ex-Dividend DateAug 11, 2022
1y Target EstN/A
  • Business Wire

    AstraZeneca Begins Tender Offer to Acquire CinCor Pharma, Inc.

    WILMINGTON, Del., January 23, 2023--AstraZeneca is commencing today, through a subsidiary, a tender offer to purchase all outstanding shares of CinCor Pharma, Inc. (CinCor), for $26 per share in cash at closing, plus a non-tradable contingent value right of $10 per share in cash payable upon a specified regulatory submission for a baxdrostat product. On 9 January 2023, AstraZeneca announced that it had entered into a definitive agreement to acquire CinCor. Following the successful closing of the

  • GlobeNewswire

    HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 18, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces, following negotiations with the China National Healthcare Security Administration (“NHSA”), ORPATHYS® (savolitinib) has been included in the updated National Reimbursement Drug List (“NRDL”) for the treatment of locally advanced or metastatic non-small cell lung cancer (“NSCLC”) adult patients with MET exon 14-skipping alterations who

  • Business Wire

    AIRSUPRA™ (PT027) approved in the US for asthma

    WILMINGTON, Del., January 11, 2023--AIRSUPRA™ (albuterol/budesonide), formerly known as PT027, has been approved in the US for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older.